

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	254	fluvastatin and polymorph	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/03/09 10:18
L2	25	fluvastatin and polymorph and monosodium	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2007/03/09 10:35

10576784

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.47

302.18

FILE 'REGISTRY' ENTERED AT 10:14:45 ON 09 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 MAR 2007 HIGHEST RN 925886-00-6

DICTIONARY FILE UPDATES: 8 MAR 2007 HIGHEST RN 925886-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "FLUVASTATIN"/CN 25

E1	1	FLUVALINATE-TOLFENPYRAD MIXT./CN
E2	1	FLUVAROL/CN
E3	1 -->	FLUVASTATIN/CN
E4	1	FLUVASTATIN HEMICALCIUM/CN
E5	1	FLUVASTATIN SODIUM/CN
E6	1	FLUVASTATIN SODIUM MONOHYDRATE/CN
E7	1	FLUVEAN/CN
E8	1	FLUVERMAL/CN
E9	1	FLUVERSIN/CN
E10	1	FLUVET/CN
E11	1	FLUVIBACTIN/CN
E12	1	FLUVIBACTINE/CN
E13	1	FLUVIOL A/CN
E14	1	FLUVIOL B/CN
E15	1	FLUVIOL C/CN
E16	1	FLUVIOL D/CN
E17	1	FLUVIOL E/CN
E18	1	FLUVION S 14/CN
E19	1	FLUVIRIN/CN
E20	1	FLUVIRUCIN A1/CN
E21	1	FLUVIRUCIN A2/CN
E22	1	FLUVIRUCIN B1/CN
E23	1	FLUVIRUCIN B1 AGLYCON/CN
E24	1	FLUVIRUCIN B2/CN
E25	1	FLUVIRUCIN B3/CN

Karen Cheng

10576784

=> S E3 OR E5

1 FLUVASTATIN/CN

1 "FLUVASTATIN SODIUM"/CN

L7

2 FLUVASTATIN/CN OR "FLUVASTATIN SODIUM"/CN

=> FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.35

312.53

FILE 'CAPLUS' ENTERED AT 10:15:17 ON 09 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Mar 2007 VOL 146 ISS 12

FILE LAST UPDATED: 8 Mar 2007 (20070308/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L7

L8 1715 L7

=> d ibib abs hitstr 1000-1010

10576784

=> d his

(FILE 'HOME' ENTERED AT 10:02:36 ON 09 MAR 2007)

FILE 'REGISTRY' ENTERED AT 10:02:47 ON 09 MAR 2007

E "7-(3-(4-FLUOROPHENYL)-1-)1-METHYLETHYL)-1H-INDOL-2-YL)-3,5-D  
E "7-(3-(4-FLUOROPHENYL)-1-(1-METHYLETHYL)-1H-INDOL-2-YL)-3,5-D

FILE 'STNGUIDE' ENTERED AT 10:04:42 ON 09 MAR 2007

FILE 'REGISTRY' ENTERED AT 10:07:50 ON 09 MAR 2007

L1 STRUCTURE UPLOADED  
L2 117 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:08:23 ON 09 MAR 2007

L3 1740 S L2

FILE 'REGISTRY' ENTERED AT 10:09:49 ON 09 MAR 2007

L4 STRUCTURE UPLOADED  
L5 44 S L4 FULL SUB=L2

FILE 'CAPLUS' ENTERED AT 10:10:21 ON 09 MAR 2007

L6 1733 S L5

FILE 'REGISTRY' ENTERED AT 10:10:33 ON 09 MAR 2007

FILE 'CAPLUS' ENTERED AT 10:10:34 ON 09 MAR 2007

FILE 'REGISTRY' ENTERED AT 10:11:05 ON 09 MAR 2007

FILE 'CAPLUS' ENTERED AT 10:11:12 ON 09 MAR 2007

FILE 'REGISTRY' ENTERED AT 10:12:55 ON 09 MAR 2007

FILE 'CAPLUS' ENTERED AT 10:13:17 ON 09 MAR 2007

FILE 'REGISTRY' ENTERED AT 10:13:27 ON 09 MAR 2007

FILE 'CAPLUS' ENTERED AT 10:13:40 ON 09 MAR 2007

FILE 'REGISTRY' ENTERED AT 10:13:53 ON 09 MAR 2007

FILE 'CAPLUS' ENTERED AT 10:14:01 ON 09 MAR 2007

FILE 'REGISTRY' ENTERED AT 10:14:45 ON 09 MAR 2007

L7 E "FLUVASTATIN"/CN 25  
2 S E3 OR E5

FILE 'CAPLUS' ENTERED AT 10:15:17 ON 09 MAR 2007

L8 1715 S L7

=> s 18 and polymorph

7795 POLYMORPH  
8882 POLYMORPHS  
13587 POLYMORPH  
(POLYMORPH OR POLYMORPHS)

Karen Cheng

10576784

L9 7 L8 AND POLYMORPH


=> d ibib abs hitstr tot

10576784

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2006:1006487 CAPLUS  
 DOCUMENT NUMBER: 145:356646  
 TITLE: Spray-drying process for the preparation of polymorph form G of fluvastatin sodium  
 INVENTOR(S): Tarur, Venkatasubramanian Radhakrishnan; Sathe, Dhananjanay Govind; Mantripragada, Narayana Rao; Bhopalkar, Rajesh; Sawant, Kamlesh Digambar; Chavan, Dattatraya Nilrutti  
 PATENT ASSIGNEE(S): USV Limited, India  
 SOURCE: PCT Int. Appl., 14pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006100686	A1	20060928	WO 2005-IN181	20050603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH IN 2005-MU317 A 20050322 AB Polymorphic form G of fluvastatin sodium, having an X-ray diffraction peak at a 2θ value of 3.48 is prepared by a process comprising spray drying a 3-10% w/v solution of fluvastatin sodium in a solvent (e.g., water) using a spray gun having an inlet temperature of 120-200° and an outlet temperature of 60-100°.				
a 93957-55-2, Fluvastatin sodium RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process) (spray-drying process for the preparation of polymorph form G of fluvastatin sodium) RN 93957-55-2 CAPLUS CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME) Relative stereochemistry. Double bond geometry as shown.				

L9 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● Na

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:385268 CAPLUS  
 DOCUMENT NUMBER: 142:435812  
 TITLE: Preparation of a polymorph of fluvastatin sodium  
 INVENTOR(S): Frenkel, Gustavo; Gilboa, Eyal  
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.  
 SOURCE: PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005040113	A1	20050506	WO 2004-US26673	20040817
WO 2005040113	A8	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, GU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2005038114 A1 20050217 US 2004-871916 20040618 EP 1719759 A2 20061108 EP 2006-17225 20040618 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK EP 1719760 A2 20061108 EP 2006-17518 20040618 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK EP 1726583 A2 20061129 EP 2006-17224 20040618 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR EP 1752448 A2 20070214 EP 2006-17519 20040618 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR CA 2541720 A1 20050506 CA 2004-2541720 20040817 EP 1667968 A1 20060614 EP 2004-781379 20040817 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK CN 1886371 A 20061227 CN 2004-80035532 20040817 US 2003-507954P P 20031003 US 2004-545466P P 20040219 US 2004-871916 A 20040618 US 2003-479182P P 20030618 US 2003-483099P P 20030630 US 2003-485748P P 20030710 US 2003-493793P P 20030811 EP 2004-755797 A3 20040618 WO 2004-US26673 W 20040817				
AB Provided are processes for preparing a polymorphic form of fluvastatin sodium with PXRD peaks at 3.8, 11.1, 12.9, 17.8 and 21.7 0.2 degrees two-theta.				

Karen Cheng

L9 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 93957-55-2P, Fluvastatin sodium  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of a polymorph of fluvastatin sodium)  
 RN 93957-55-2 CAPLUS  
 CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)  
 Relative stereochemistry.  
 Double bond geometry as shown.



● Na

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

look WO/02/36563

10576784

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:371218 CAPLUS  
DOCUMENT NUMBER: 142:417153  
TITLE: Crystalline form of fluvastatin sodium  
INVENTOR(S): Van Der Schaaf, Paul Adriaan; Blatter, Fritz;  
Szelagiewicz, Martin  
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.  
SOURCE: PCT Int. Appl., 11 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037787	A1	20050428	WO 2004-EP52449	20041006
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2006241167	A1	20061026	US 2006-576784	20060421

PRIORITY APPLN. INFO.: EP 2003-103841 A 20031016  
WO 2004-EP52449 W 20041006


AB A novel crystalline form of Fluvastatin sodium hydrate is described, referred to hereinafter as polymorphic Form G. Furthermore, processes for the preparation of this crystalline form and pharmaceutical compns. comprising this crystalline form are reported. For example, fluvastatin sodium Form A 300 mg were suspended in 1 mL water and stirred for 18 h. The solid residue was separated by filtration. Without any further drying, the obtained solid paste showed a characteristic x-ray powder diffraction pattern for Form G.

IT 93957-55-2, Fluvastatin sodium  
RI: RCT (Reactant); RACT (Reactant or reagent)  
(crystalline form of fluvastatin sodium hydrate)

RN 93957-55-2 CAPLUS  
CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:955217 CAPLUS  
DOCUMENT NUMBER: 141:395334  
TITLE: Preparation of polymorphic crystalline fluvastatin sodium  
INVENTOR(S): Suri, Sanjay; Sarin, Gurdeep Singh  
PATENT ASSIGNEE(S): Morepen Laboratories Ltd., India  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096765	A2	20041111	WO 2004-IN121	20040430
WO 2004096765	A3	20050127		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: IN 2003-DE656 A 20030501  
OTHER SOURCE(S): CASREACT 141:395334


AB Crystalline polymorphic forms of fluvastatin sodium and its hydrates are prepared by the reaction of the Me ester of fluvastatin with sodium hydroxide followed by the addition of aliphatic ethers (e.g., THF) as an antisolvent to facilitate precipitating the crystal polymorph of fluvastatin sodium.

IT 93957-55-2P, Fluvastatin sodium  
RI: PRE (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of polymorphic crystalline fluvastatin sodium)

RN 93957-55-2 CAPLUS  
CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
Double bond geometry as shown.

L9 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



10576784

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2004:962842 CAPLUS  
 DOCUMENT NUMBER: 141:400924  
 TITLE: Stabilization of polymorphic forms of fluvastatin sodium in solid pharmaceutical formulations  
 INVENTOR(S): Stamm, Gerold U.; Kraass, Peter  
 PATENT ASSIGNEE(S): Ratiopharm GmbH, Germany  
 SOURCE: Ger. Offen., 9 pp.  
 CODEN: GXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10316087	A1	20041111	DE 2003-10316087	20030408

PRIORITY APPLN. INFO.: DE 2003-10316087 20030408

AB The invention concerns the stabilization of polymorphic forms of fluvastatin sodium in solid pharmaceutical formulations by setting the water content of the formulations at a predet. value and maintaining this water content during storage; to maintain the water content formulations are coated or packaged in appropriate materials. Thus tablets were prepared by using (mg/tablet): racemate fluvastatin sodium, polymorph D form, having water content 9.6 weight/weight 80.0; sorbit with water content 1.2 weight/weight 20.0; microcryst. cellulose with water content 4.5 weight/weight 40.0; calcium hydrogen phosphate dihydrate with water content 22.0 weight/weight 40; sodium dihydrogen phosphate dihydrate with water content 26.0 weight/weight 15; total water content of a 195 mg tablet core was 11.8 weight/weight. Tablets were coated with (mg/tablet): Pharmacoat 606 5.0;

PEG 4000 0.25; talc 2.0; stearic acid 0.75.

IT 93957-55-2, Fluvastatin sodium  
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (stabilization of polymorphic forms of fluvastatin sodium in pharmaceutical formulations)

RN 93957-55-2 CAPLUS  
 CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry as shown.

L9 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:893756 CAPLUS  
 DOCUMENT NUMBER: 140:120211  
 TITLE: [R\*,S\*-(E)]-(±)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, monosodium salt intermediate. FDME crystal forms  
 AUTHOR(S): Anon.  
 CORPORATE SOURCE: USA  
 SOURCE: IP.com Journal (2003), 3(9), 11 (No. IPCOM0000188000)  
 PUBLISHER: 11 Aug 2003  
 DOCUMENT TYPE: IP.com, Inc.  
 LANGUAGE: Journal: Patent  
 PATENT INFORMATION: English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IP 188000		20030811		


PRIORITY APPLN. INFO.: IP 2003-188000 20030811

AB [R\*,S\*-(E)]-(±)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid Me ester (FDME) is used as an intermediate in the preparation of the title compound Here, the x-ray powder diffraction data of 2 crystal forms of FDME are given.

IT 93957-55-2  
 RL: PEP (Properties)  
 (x-ray powder diffraction data for α and β crystal forms of)


RN 93957-55-2 CAPLUS  
 CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.  
 Double bond geometry as shown.



● Na

L9 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● Na

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1998:42379 CAPLUS  
 DOCUMENT NUMBER: 128:119663  
 TITLE: Polymorphs of fluvastatin sodium  
 INVENTOR(S): Horvath, Karol  
 PATENT ASSIGNEE(S): Astra Aktiebolag (Publ), Swed.; Horvath, Karol  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9749681	A1	19971231	WO 1997-SE1097	19970618
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9733662	A	19980114	AU 1997-33662	19970618
EP 907639	B1	19990414	EP 1997-929654	19970618
EP 907639	B1	20030312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000512992	T	20001003	JP 1998-502821	19970618
AT 234282	T	20030315	AT 1997-929654	19970618
PT 907639	T	20030630	PT 1997-929654	19970618
ES 2194202	T3	20031116	ES 1997-929654	19970618
US 6124340	A	20000926	US 1997-975203	19970731
			SE 1996-2477	A 19960624
			SE 1997-751	A 19970303
			WO 1997-SE1097	W 19970618

AB This invention relates to a novel form of the HMG-CoA reductase inhibitor fluvastatin, more specifically to a highly crystalline form of fluvastatin sodium, referred to as fluvastatin sodium form B. The invention also relates to processes for the production of fluvastatin sodium form B, to pharmaceutical compns. comprising fluvastatin sodium form B, and to the use of fluvastatin sodium form B in cardiovascular diseases treatment. Thus, lyophilized fluvastatin sodium form A was dissolved in a mixture of EtOH and water and the solution stirred for 5 min. MeCN was added as a precipitating solvent and the solution was seeded with the form B crystals to induce crystallization of fluvastatin sodium monohydrate form B.

IT 93957-55-2, Fluvastatin sodium  
 RL: PEP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (polymorphs of fluvastatin sodium)

RN 93957-55-2 CAPLUS  
 CN 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.  
 Double bond geometry as shown.

Karen Cheng



10576784

L9 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



Karen Cheng